Skip to main content

Table 1 Characteristics of enrolled patients

From: Effect of the duration of the capecitabine regimen following colon cancer surgery in an elderly population: a retrospective cohort study

Characteristics

Postoperative capecitabine duration

P value

0

 ≤ 12 weeks

 ≤ 24 weeks

No. of participants

143

79

35

 

  Age (years), mean (SD)

77.69 (4.90)

73.57 (2.77)

73.34 (2.99)

 < 0.001

   ≥ 70, < 75

43 (30.07%)

46 (58.23%)

25 (71.43%)

 

   ≥ 75, < 80

43 (30.07%)

33 (41.77%)

8 (22.86%)

 

   ≥ 80

57 (39.86%)

0 (0.00%)

2 (5.71%)

 

Gender, N (%)

   

0.421

  Male

85 (59.44%)

54 (68.35%)

22 (62.86%)

 

  Female

58 (40.56%)

25 (31.65%)

13 (37.14%)

 

T stage, N (%)

   

0.177

  1–2

8 (5.59%)

2 (2.53%)

1 (2.86%)

  3

118 (82.52%)

68 (86.08%)

25 (71.43%)

  4

17 (11.89%)

9 (11.39%)

9 (25.71%)

 

N stage, N (%)

   

0.832

  0

74 (51.75%)

36 (45.57%)

18 (51.43%)

  1

57 (39.86%)

33 (41.77%)

14 (40.00%)

  2

12 (8.39%)

10 (12.66%)

3 (8.57%)

Stage, N (%)

   

0.664

  II

74 (51.75%)

36 (45.57%)

18 (51.43%)

  III

69 (48.25%)

43 (54.43%)

17 (48.57%)

Histological type

   

0.883

  Common type

122 (85.31%)

68 (86.08%)

31 (88.57%)

 

  Special typea

21 (14.69%)

11 (13.92%)

4 (11.43%)

 

CA199, N (%)

   

0.232

  Normal

122 (85.31%)

60 (76.92%)

27 (77.14%)

 

  Elevated

21 (14.69%)

18 (23.08%)

8 (22.86%)

 

CEA, N (%)

   

0.830

  Normal

92 (64.34%)

48 (60.76%)

23 (65.71%)

 

  Elevated

51 (35.66%)

31 (39.24%)

12 (34.29%)

 

MMR status

   

0.021

  dMMR

15 (10.49%)

3 (3.80%)

2 (5.71%)

 

  pMMR

106 (74.13%)

51 (64.56%)

28 (80.00%)

 

  Unknown

22 (15.38%)

25 (31.65%)

5 (14.29%)

 

  Charlson comorbidity index

   

 < 0.001

   ≤ 4

88 (61.54%)

75 (94.94%)

34 (97.14%)

 

   > 4

55 (38.46%)

4 (5.06%)

1 (2.86%)

 
  1. Notes: aSpecial type adenocarcinoma includes mucinous, signet ring cell, medullary, and undifferentiated variants
  2. Abbreviations: CA carcinoma antigen; CEA carcinoembryonic antigen; MMR mismatch repair; dMMR mismatch repair deficiency; pMMR proficient mismatch repair